What are the Clinical Implications of Immune Checkpoint Inhibitors?
Immune checkpoint inhibitors have shown remarkable efficacy in treating various cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. These therapies can lead to durable responses and have significantly improved the prognosis for many patients. However, they are also associated with immune-related adverse events (irAEs) due to the enhanced immune activation, which can affect any organ system and require careful management.
